Epidemiology and disease characteristics of myelofibrosis: a comparative analysis between Italy and global perspectives

Myelofibrosis (MF) is a clonal disorder of hematopoietic stem cells characterized by altered bone marrow function and fibrosis. The aim of this narrative review is to report on the most recent epidemiologic data and to discuss features of MF and current strategies for the management of this conditio...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Frontiers in Oncology
المؤلفون الرئيسيون:	Massimo Breccia, Francesca Palandri, Nicola Polverelli, Morena Caira, Michela Berluti, Giuseppe A. Palumbo, Valerio De Stefano
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Frontiers Media S.A. 2024-07-01
الموضوعات:	CALR JAK2 MPL myelofibrosis myeloproliferative neoplasms secondary fibrosis
الوصول للمادة أونلاين:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1382872/full

مواد مشابهة

Biology of Myeloproliferative Malignancies
حسب: AL Melikyan, وآخرون
منشور في: (2016-07-01)

Editorial: Biological and clinical implications of the mutational landscape in myeloproliferative neoplasms
حسب: Giuseppe Gaetano Loscocco, وآخرون
منشور في: (2024-07-01)

CLINICAL AND LABORATORY FEATURES OF ESSENTIAL THROMBOCYTOSIS AND PRIMARY MYELOFIBROSIS DEPENDING ON JAK2 AND CALR1 MUTATION STATUS
حسب: E. G. lisina, وآخرون
منشور في: (2017-10-01)

Transcriptomic Analysis Reveals JAK2/MPL-Independent Effects of Calreticulin Mutations in a <i>C. elegans</i> Model
حسب: Ana Guijarro-Hernández, وآخرون
منشور في: (2023-01-01)

Diagnosis and Management of Essential Thrombocythemia: A Comprehensive Review
حسب: Sandra LAZAR, وآخرون
منشور في: (2024-09-01)

Prevalence and clinicopathological features of driver gene mutations profile in BCR:ABL1 negative classical myeloproliferative neoplasm—A single-center study from North India
حسب: Khaliqur Rahman, وآخرون
منشور في: (2024-12-01)

The clinical relevance of broad mutational screening of myeloproliferative neoplasms at diagnosis
حسب: Helna Pettersson, وآخرون
منشور في: (2023-08-01)

Analysis of somatic mutations in the <i>JAK2</i>, <i>CALR</i>, <i>MPL</i> and <i>ASXL1</i> genes and evaluation of their impact on the survival of patients with myelofibrosis
حسب: T. N. Subbotina, وآخرون
منشور في: (2023-03-01)

Arginase‐1+ bone marrow myeloid cells are reduced in myeloproliferative neoplasms and correlate with clinical phenotype, fibrosis, and molecular driver
حسب: Arturo Bonometti, وآخرون
منشور في: (2023-04-01)

MPN: The Molecular Drivers of Disease Initiation, Progression and Transformation and their Effect on Treatment
حسب: Julian Grabek, وآخرون
منشور في: (2020-08-01)

Genomics of clonal evolution in a rare essential thrombocythemia with coexisting Type 2 CALR and MPL S204P mutations
حسب: Jing Wang, وآخرون
منشور في: (2023-12-01)

Case report: Application of targeted NGS for the detection of non-canonical driver variants in MPN
حسب: Jin Zhang, وآخرون
منشور في: (2023-06-01)

The characteristics of CALR mutations in myeloproliferative neoplasms: a clinical experience from a tertiary care center in Qatar and a literature review
حسب: Mostafa Najim, وآخرون
منشور في: (2024-12-01)

Molecular Genetic Markers and Clinical Characteristics of Essential Thrombocythemia
حسب: AA Zhernyakova, وآخرون
منشور في: (2017-07-01)

JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis
حسب: Andrew T. Kuykendall, وآخرون
منشور في: (2021-08-01)

Clinical and hematological factors predicting the effectiveness of ruxolitinib in primary and secondary myelofibrosis. Results of a prospective single-center study
حسب: O. Yu. Vinogradova, وآخرون
منشور في: (2024-09-01)

Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms
حسب: Giuseppe G. Loscocco, وآخرون
منشور في: (2021-08-01)

Focus on Osteosclerotic Progression in Primary Myelofibrosis
حسب: Mariarita Spampinato, وآخرون
منشور في: (2021-01-01)

Management of paroxysmal nocturnal hemoglobinuria in CALR mutated post‐essential thrombocythemia myelofibrosis: A case report
حسب: Mahija Cheekati, وآخرون
منشور في: (2024-04-01)

Concomitant BCR-ABL1 positive chronic myelogenous leukemia emerging in a patient with MPL W515L associated primary myelofibrosis
حسب: Juan C. Gomez-Gelvez, MD, وآخرون
منشور في: (2016-03-01)

Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients
حسب: Barbara Mora, وآخرون
منشور في: (2019-08-01)

Spatial-transcriptomic profiling: a new lens for understanding myelofibrosis pathophysiology
حسب: Edoardo Peroni, وآخرون
منشور في: (2024-10-01)

Distinct clinical, molecular, and treatment response profiles in primary and secondary myelofibrosis: a single-center retrospective study
حسب: Wenya Liu, وآخرون
منشور في: (2026-12-01)

Splenomegaly in myelofibrosis—new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors
حسب: Randhawa Jasleen, وآخرون
منشور في: (2012-08-01)

Risk‐adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis
حسب: Naveen Pemmaraju, وآخرون
منشور في: (2022-11-01)

Complicated course of portal hypertension on the background of primary myelofibrosis: a clinical case
حسب: V.B. Yagmur, وآخرون
منشور في: (2025-03-01)

Molecular markers as possible efficacy predictors of targeted therapy for myelofibrosis: single-center study
حسب: O. Yu. Vinogradova, وآخرون
منشور في: (2023-12-01)

Chronic myeloproliferative neoplasms with concomitant CALR mutation and BCR::ABL1 translocation: diagnostic and therapeutic implications of a rare hybrid disease
حسب: Magda Zanelli, وآخرون
منشور في: (2024-03-01)

Recent progress of JAK inhibitors for hematological disorders
حسب: Keita Kirito
منشور في: (2023-07-01)

MPL W515L/K Mutations in Chronic Myeloproliferative Neoplasms
حسب: Timur Selçuk Akpınar, وآخرون
منشور في: (2013-03-01)

Programmed death‐ligand 1 expression in patients with primary or secondary myelofibrosis
حسب: Moayed Ibrahim, وآخرون
منشور في: (2024-09-01)

The effects of mutational profiles on phenotypic presentation of myeloproliferative neoplasm subtypes in Bosnia: 18 year follow-up
حسب: Amina Kurtovic-Kozaric, وآخرون
منشور في: (2020-05-01)

Myelofibrosis Models: Literature Review and Own Data
حسب: AA Silyutina, وآخرون
منشور في: (2017-01-01)

Hereditary spherocytosis concomitant with JAK2V617F-positive primary myelofibrosis: a case report
حسب: Chi-E Qiu, وآخرون
منشور في: (2025-10-01)

Primary myelofibrosis: current therapeutic options
حسب: Paula de Melo Campos

Primary and secondary myelofibrosis: ophthalmological manifestations at onset and during therapy
حسب: O. Yu. Vinogradova, وآخرون
منشور في: (2025-03-01)

Frequency of Non-Type I/II <i>CALR</i> Mutations in Patients Undergoing Molecular Diagnostics for Myeloproliferative Neoplasms
حسب: Tatiana Makarik, وآخرون
منشور في: (2026-05-01)

Transcriptomic comparison of bone marrow CD34 + cells and peripheral blood neutrophils from ET patients with JAK2 or CALR mutations
حسب: Ana Guijarro-Hernández, وآخرون
منشور في: (2023-08-01)

Janus kinase V617F mutation detection in patients with myelofibrosis
حسب: Nikolova D, وآخرون
منشور في: (2019-08-01)

JAK2 V617F prevalence in Brazilian patients with polycythemia vera, idiopathic myelofibrosis and essential thrombocythemia
حسب: Bárbara da Costa Reis Monte-Mór, وآخرون
منشور في: (2007-03-01)